Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Neuren Pharmaceuticals (NEU) opens its Phase Two clinical trial of its NNZ-2591 drug in Angelman syndrome (AS) for enrollment
  • The trial is being conducted at three hospitals in Brisbane, Melbourne and Sydney under an investigational new drug application with the US Food and Drug Administration
  • Neuren says the trial will aim to examine the safety, tolerability, pharmacokinetics and efficacy of NNZ-2591 over 13 weeks of treatment
  • In parallel with the Phase Two trial, Neuren is also executing the foundational work to prepare for Phase Three development across multiple indications
  • Shares in Neuren are trading grey at $3.95 per share at 12:22 pm AEST

Neuren Pharmaceuticals (NEU) has opened its Phase Two clinical trial of its NNZ-2591 drug in Angelman syndrome (AS) for enrollment.

The first subjects are expected to enter the trial “imminently” at the Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children’s Health Queensland Hospital.

The trial is being conducted at three hospitals in Brisbane, Melbourne and Sydney under an investigational new drug application with the US Food and Drug Administration.

Neuren said the aim of the trial was to examine the safety, tolerability, pharmacokinetics and efficacy of NNZ-2591 over 13 weeks of treatment under which all subjects will receive an oral liquid dose twice daily.

CEO Jon Pilcher said Angelman syndrome was a “seriously debilitating” condition with no approved medicines.

“In the ube3a knockout mouse model of Angelman, treatment with NNZ-2591 normalized all the deficits, so we are now eager to observe the effects of treatment in children,” Mr Pilcher said.

In parallel with the Phase Two trial, Neuren is also executing the foundational work to prepare for Phase Three development across multiple indications.

Angelman syndrome is characterized by severe developmental delay and learning disabilities that become noticeable by the age of six to 12 months.

Shares in Neuren were trading grey at $3.95 per share at 12:22 pm AEST.

NEU by the numbers
More From The Market Herald

" Altech Chemicals (ASX:ATC) advances financing activities for Malaysia HPA project

Altech Chemicals (ASX:ATC) has advanced project financing activities for its Malaysia high-purity alumina (HPA) project.

" Booktopia (ASX:BKG) to open new customer fulfilment centre

Booktopia (ASX:BKG) has secured a new, a larger 20,000 metres square clean skin customer fulfilment centre…

" Alligator Energy (ASX:AGE) commences first exploration work on Nabarlek North Project, NT

Alligator Energy (ASX:AGE) has commenced its airborne gravity work at the Nabarlek North Project in the…

" Jade Gas (ASX:JGH) expands Mongolian drilling program

Jade Gas (ASX:JGH) expands the drilling program at the Tavantolgoi XXXIII Coal Bed Methane gas project…